Figure 6
From: EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
Xenograft transplantation using NOD/SCID mice and histopathological examination of xenograft tumors. (A) Tumor growth curve of the recipient mice treated with sorafenib and/or UNC1999 (repeated measures ANOVA, *p < 0.05). (B) Representative images of recipient mice treated with sorafenib and/or UNC1999 6 weeks after the transplantation. (C) Xenograft tumors were subjected to Hematoxylin and eosin staining and immunohistochemical staining. Scale bar = 50 µm. (D) Immunostaining of CASP3 and TUNEL assay. Arrows indicate TUNEL-positive cells. Scale bar = 50 µm.
